More on RLMD
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.20 |
|
|||
| Open | $4.15 | ||||
| 52 Wk High | $4.10 | ||||
| 52 Wk Low | $0.87 | ||||
| Day High | $4.17 | ||||
| Day Low | $4.06 | ||||
| P/E | N/A | ||||
| EPS | $0.00 | ||||
| Volume | 2,069,829 | ||||
- Form 4 RELMADA THERAPEUTICS, For: Sep 09 Filed by: TRAVERSA SERGIO
- Form 4 RELMADA THERAPEUTICS, For: Sep 09 Filed by: Shenouda Maged
- Form SCHEDULE 13G/A RELMADA THERAPEUTICS, Filed by: Squadron Capital Management LLC
- Mizuho sees a chance to buy this biotech stock after recent weakness
- Mizuho Reiterates Outperform Rating on Relmada Therapeutics Inc (RLMD)
- Relmada Therapeutics (RLMD) Tops Q2 EPS by 8c
- Form 8-K RELMADA THERAPEUTICS, For: Aug 06
- Form 10-Q RELMADA THERAPEUTICS, For: Jun 30
- Relmada Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
- Form SCHEDULE 13G RELMADA THERAPEUTICS, Filed by: BlackRock, Inc.
Entities mentioned with RLMD
- FDA | View Related Stories »
- Earnings | View Related Stories »
- 13G | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Jefferies & Co | View Related Stories »
- Definitive Agreement | View Related Stories »
- Show More...
